Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Maintains Buy Rating and $3.50 PT on 22nd Century Group (XXII) Ahead of Q4 Report
-
Chardan Capital Maintains Buy Rating and $10 PT on Vuzix Corp. (VUZI); 'Strong Start to 2017 from M300 and Toshiba'
-
Chardan Capital Reiterates Buy Rating and $11.50 PT on ORBCOMM (ORBC); 'Strong Backlog and Robust Pipeline'
-
Teladoc (TDOC) PT Raised to $28 at Chardan Capital Markets Following 4Q Top-Line and Bottom-Line Beats
-
La Jolla Pharma (LJPC) PT Raised to $90 at Chardan Capital Markets Following Robust LJPC-501 Phase 3 Topline Results
-
Chardan Capital Maintains Hold Rating and $1.50 PT on Novavax (NVAX) Following 4Q Report; New RSV F Clinical Data is Next Catalyst
-
Chardan Capital Markets Upgrades Globalstar (GSAT) to Buy
-
Chardan Capital Markets Starts OncoCyte Corp (OCX) at Buy
-
Chardan Capital Markets Reiterates Buy on NICE Systems (NICE) Following 4Q Report
-
Chardan Capital Reiterates Neutral Rating and $35 PT on DigitalGlobe (DGI) Following Takeover Reports
-
Teladoc (TDOC): More Confident After Management Meetings - Chardan
-
BioTime, Inc. Announces Closing of Public Offering of Common Stock
-
Chardan Capital Markets Remains Bullish on NICE Systems (NICE) Ahead of 4Q Report
-
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Neutral
-
Chardan Capital Markets Reiterates Buy on HealthEquity (HQY) Following Investor Call
-
BioTime (BTX) Prices 6.5M Common Stock Offering at $2.70/Share
-
BioTime, Inc. Announces Pricing of Public Offering of Common Stock
-
HealthEquity (HQY): Strong Preannouncement With Guidance In Line - Chardan
-
MYOS RENS Tech (MYOS) Reports $2.13M Registered Direct Offering of Common Stock
-
MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering
-
Pre-Open Movers 02/03: (PXLW) (DATA) (PTN) Higher; (DECK) (IDXG) (FEYE) (GPRO) (AMZN) Lower (more...)
-
Chardan Capital Markets Downgrades Clovis Oncology (CLVS) to Sell
-
Chardan Capital Markets Starts Social Reality (SRAX) at Buy, $9 PT
-
uniQure (QURE) Breakthrough Therapy Designation an 'Important Positive' - Chardan Capital Markets
-
Emergent BioSolutions (EBS): 3 Key Points From NDR - Chardan
-
KeyW Holding (KEYW) 8.5M Share Offering Prices at $10.50
-
KeyW Announces Pricing of Public Offering of Common Stock
-
KeyW (KEYW) Announces 8.5M Public Offering of Common Stock
-
KeyW Announces Public Offering of Common Stock
-
AveXis (AVXS) Ramps 11% on Bullish Analyst Call, $100 PT
-
AveXis (AVXS) PT Raised to $100 at Chardan Capital Markets
-
La Jolla Pharma (LJPC) a Top Pick at Chardan Capital Markets Into Data
-
PlacementTracker Publishes 2016 Private Placement Market League Tables
-
NICE Systems (NICE): Raising PT After Acquisition Closes - Chardan
-
Alnylam Pharmaceuticals (ALNY) PT Raised 41% at Chardan Capital Markets to $97
-
Medicines Co. (MDCO): Top Pick for 2017 - Chardan
-
Chardan Capital Markets Starts Benefitfocus (BNFT) at Buy, $36 PT
-
Chardan Capital Weighs in on 22nd Century Group (XXII) as FDA Responds to MRTP Application
-
Microbot Medical (MBOT) to Sell 700K Shares for $3.5M in Direct Offering
-
Microbot Medical Inc. Announces $3.5 Million Registered Direct Offering
-
Social Reality (SRAX) Announces $4M Direct Offering
-
Social Reality Announces Offering for $4 Million
-
Spinraza Label Suggests AveXis (AVXS) AVXS-101 Should Be The Superior Product - Chardan Capital Markets
-
GlobalStar (GSAT): FCC Approves TLPS - Chardan Capital Markets
-
Northwest Biotherapeutics (NWBO) to Sell 28.6M Shares at $0.35/Share
-
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS
-
Chardan Capital Markets Upgrades Clovis Oncology (CLVS) to Neutral
-
Origo Acquisition Corporation and Aina Le’a, Inc. Agree to Business Combination
-
Chardan Capital Markets Downgrades iPass Inc. (IPAS) to Neutral
-
Chardan Capital Markets Upgrades Profire Energy (PFIE) to Buy

